NCT06524505Recruiting
Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression
Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression: a Double-blind, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
The aim of this study is to evaluate the feasibility and efficacy of deep transcranial magnetic stimulation (dTMS) as an add-on treatment for bipolar depression. Meanwhile, we aim to evaluate the effect of dTMS on cognitive function of bipolar depressive patients. We hypothesize dTMS would improve depressive symptoms and cognitive function in bipolar disorder.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 23 Jul 2024
- Start date
- 1 Aug 2024
- Primary completion date
- 1 Sept 2025
- Lead sponsor
- Tianjin Anding Hospital
- Diseases
- Bipolar disorder
- NCT number
- NCT06524505
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 Aug 2024 to the primary completion date, 1 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- receipt of electroconvulsive therapy, rTMS, transcranial direct current stimulation, transcranial alternating current stimulation, or other neurostimulation treatments within the previous 3 months;
Other illness
- a lifetime history of other psychiatric disorders, neurological diseases, or severe brain injury;
- contraindications to magnetic stimulation, including epilepsy, cardiovascular disorders, or metallic implants in the head;
Other
- the presence of hypomanic/manic symptoms at baseline or a score greater than 12 on the Young Mania Rating Scale (YMRS);
- pregnancy or lactation.
Who the study is looking for
- Confirmed diagnosis of bipolar depression;
- age between 18 and 65 years;
- a 17-item Hamilton Depression Rating Scale (HDRS-17) score \>= 17,
- a stable pharmacological regimen maintained for at least 4 weeks prior to the beginning of the treatment phase ;
- for participants who had previously received antidepressant therapy, a minimum 4-week washout period followed by re-evaluation.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Anding Hospital Coordinator of this site? Confirm its status | Tianjin | China | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.